vs
FENNEC PHARMACEUTICALS INC.（FENC）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
FENNEC PHARMACEUTICALS INC.的季度营收约是林德的1.6倍（$13.8M vs $8.8M），FENNEC PHARMACEUTICALS INC.同比增速更快（73.8% vs 8.2%），过去两年FENNEC PHARMACEUTICALS INC.的营收复合增速更高（-26.3% vs -96.7%）
Fennec制药是一家生物制药企业，专注于开发和商业化可降低儿童癌症患者治疗相关副作用的特种疗法，核心产品针对化疗引发的耳毒性，主要市场覆盖北美，服务肿瘤诊疗机构及儿童肿瘤患者群体。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
FENC vs LIN — 直观对比
营收规模更大
FENC
是对方的1.6倍
$8.8M
营收增速更快
FENC
高出65.6%
8.2%
两年增速更快
FENC
近两年复合增速
-96.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $8.8M |
| 净利润 | $-4.8M | — |
| 毛利率 | — | 48.5% |
| 营业利润率 | -18.5% | 27.8% |
| 净利率 | -34.7% | — |
| 营收同比 | 73.8% | 8.2% |
| 净利润同比 | -141.1% | — |
| 每股收益（稀释后） | $-0.17 | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FENCLIN
| Q1 26 | — | $8.8M | ||
| Q4 25 | $13.8M | $8.8B | ||
| Q3 25 | $12.5M | $8.6B | ||
| Q2 25 | $9.7M | $8.5B | ||
| Q1 25 | $8.8M | $8.1B | ||
| Q4 24 | $7.9M | $8.3B | ||
| Q3 24 | $7.0M | $8.4B | ||
| Q2 24 | $7.3M | $8.3B |
净利润FENCLIN
| Q1 26 | — | — | ||
| Q4 25 | $-4.8M | $1.5B | ||
| Q3 25 | $-638.0K | $1.9B | ||
| Q2 25 | $-3.2M | $1.8B | ||
| Q1 25 | $-1.2M | $1.7B | ||
| Q4 24 | $-2.0M | $1.7B | ||
| Q3 24 | $-5.7M | $1.6B | ||
| Q2 24 | $-5.6M | $1.7B |
毛利率FENCLIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率FENCLIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | -18.5% | 23.0% | ||
| Q3 25 | -1.5% | 27.5% | ||
| Q2 25 | -28.3% | 27.7% | ||
| Q1 25 | -9.2% | 26.9% | ||
| Q4 24 | -11.8% | 27.4% | ||
| Q3 24 | -74.6% | 25.0% | ||
| Q2 24 | -69.4% | 26.4% |
净利率FENCLIN
| Q1 26 | — | — | ||
| Q4 25 | -34.7% | 17.5% | ||
| Q3 25 | -5.1% | 22.4% | ||
| Q2 25 | -32.7% | 20.8% | ||
| Q1 25 | -13.3% | 20.6% | ||
| Q4 24 | -25.0% | 20.8% | ||
| Q3 24 | -82.2% | 18.5% | ||
| Q2 24 | -76.5% | 20.1% |
每股收益（稀释后）FENCLIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | $-0.17 | $3.28 | ||
| Q3 25 | $-0.02 | $4.09 | ||
| Q2 25 | $-0.11 | $3.73 | ||
| Q1 25 | $-0.04 | $3.51 | ||
| Q4 24 | $-0.02 | $3.61 | ||
| Q3 24 | $-0.21 | $3.22 | ||
| Q2 24 | $-0.20 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.8M | $4.0M |
| 总债务越低越好 | — | $24.7M |
| 股东权益账面价值 | $35.5M | $40.1M |
| 总资产 | $70.6M | $86.3M |
| 负债/权益比越低杠杆越低 | — | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资FENCLIN
| Q1 26 | — | $4.0M | ||
| Q4 25 | $36.8M | $5.1B | ||
| Q3 25 | $21.9M | $4.5B | ||
| Q2 25 | $18.7M | $4.8B | ||
| Q1 25 | $22.7M | $5.3B | ||
| Q4 24 | $26.6M | $4.8B | ||
| Q3 24 | $40.3M | $5.2B | ||
| Q2 24 | $43.1M | $4.6B |
总债务FENCLIN
| Q1 26 | — | $24.7M | ||
| Q4 25 | — | $20.7B | ||
| Q3 25 | $19.4M | $18.6B | ||
| Q2 25 | $19.4M | $19.7B | ||
| Q1 25 | $19.4M | $17.6B | ||
| Q4 24 | $19.3M | $15.3B | ||
| Q3 24 | $32.1M | $17.5B | ||
| Q2 24 | $31.8M | $16.9B |
股东权益FENCLIN
| Q1 26 | — | $40.1M | ||
| Q4 25 | $35.5M | $38.2B | ||
| Q3 25 | $-4.5M | $38.6B | ||
| Q2 25 | $-7.5M | $38.5B | ||
| Q1 25 | $-5.9M | $38.0B | ||
| Q4 24 | $-5.9M | $38.1B | ||
| Q3 24 | $-5.2M | $39.2B | ||
| Q2 24 | $-1.4M | $38.2B |
总资产FENCLIN
| Q1 26 | — | $86.3M | ||
| Q4 25 | $70.6M | $86.8B | ||
| Q3 25 | $49.3M | $86.0B | ||
| Q2 25 | $44.9M | $86.1B | ||
| Q1 25 | $46.4M | $82.7B | ||
| Q4 24 | $44.9M | $80.1B | ||
| Q3 24 | $58.9M | $82.5B | ||
| Q2 24 | $63.2M | $80.2B |
负债/权益比FENCLIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.0M | — |
| 自由现金流经营现金流 - 资本支出 | — | $898.0K |
| 自由现金流率自由现金流/营收 | — | 10.2% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $4.2B |
8季度趋势，按日历期对齐
经营现金流FENCLIN
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $3.0B | ||
| Q3 25 | $1.5M | $2.9B | ||
| Q2 25 | $-3.7M | $2.2B | ||
| Q1 25 | $-4.3M | $2.2B | ||
| Q4 24 | $-1.5M | $2.8B | ||
| Q3 24 | $-2.2M | $2.7B | ||
| Q2 24 | $-8.4M | $1.9B |
自由现金流FENCLIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $954.0M | ||
| Q1 25 | — | $891.0M | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $796.0M |
自由现金流率FENCLIN
| Q1 26 | — | 10.2% | ||
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | — | 18.8% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 9.6% |
资本支出强度FENCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 16.6% | ||
| Q3 25 | — | 14.8% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | — | 15.1% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | 13.7% |
现金转化率FENCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
